Učitavanje...

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

PURPOSE: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. However, there are conflicting findings regarding the potential benefit of adjuvant EGFR-TKI in patients with lung cancer harboring E...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Oxnard, Geoffrey R., Janjigian, Yelena Y., Arcila, Maria E., Sima, Camelia S., Kass, Samantha L., Riely, Gregory J., Pao, William, Kris, Mark G., Ladanyi, Marc, Azzoli, Christopher G., Miller, Vincent A.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186869/
https://ncbi.nlm.nih.gov/pubmed/21831955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1080
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!